liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant Mycobacterium tuberculosis
Karolinska Institute, Sweden; Karolinska University, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Medical Microbiology. Linköping University, Faculty of Health Sciences. Linnaeus University, Sweden.
Uppsala University, Sweden.
Karolinska Institute, Sweden; Karolinska University, Sweden.
Show others and affiliations
2014 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 58, no 12, 7557-7559 p.Article in journal (Refereed) Published
Abstract [en]

We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB). The MIC distribution of SXT was 0.125/2.4 to 2/38 mg/liter for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for the pansusceptible strain H37Rv was 76 mg/liter. In an exploratory analysis using a ratio of the unbound area under the concentration-time curve from 0 to 24 h over MIC (fAUC(0-24)/MIC) using greater than= 25 as a potential target, the cumulative fraction response was greater than= 90% at doses of greater than= 2,400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.

Place, publisher, year, edition, pages
American Society for Microbiology , 2014. Vol. 58, no 12, 7557-7559 p.
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:liu:diva-112994DOI: 10.1128/AAC.02995-14ISI: 000345221000065PubMedID: 25246405OAI: oai:DiVA.org:liu-112994DiVA: diva2:779163
Note

Funding Agencies|Swedish Society of Medicine [SLS 169241]; Marianne and Marcus Wallenberg Foundation; Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation); Swedish Society of Antimicrobial Chemotherapy

Available from: 2015-01-12 Created: 2015-01-08 Last updated: 2017-12-05

Open Access in DiVA

fulltext(708 kB)107 downloads
File information
File name FULLTEXT01.pdfFile size 708 kBChecksum SHA-512
26a902e2273ea65b4fbfb2e347141b5f873c4839d9724854d3dbbb38de4a4af90f6599b28826ec9f54a88bfd40240b06d74e499b9290a1405af6725ab9b9eb53
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Schön, Thomas

Search in DiVA

By author/editor
Schön, ThomasLarsson, Marie C
By organisation
Medical MicrobiologyFaculty of Health SciencesDivision of Microbiology and Molecular Medicine
In the same journal
Antimicrobial Agents and Chemotherapy
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 107 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 106 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf